Last updated 44 hours ago
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
600 patients around the world
Available in Argentina, United States
Eli Lilly and Company
4Research sites
600Patients around the world
This study is for people with
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have a Body Mass Index (BMI) at screening.≥ 30 kilogram per square meter (kg/m2) OR.≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease.Have at least one unsuccessful attempt to lose weight by dieting.
- Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening.Have a prior or planned surgical treatment for obesity.Have type 1 diabetes or type 2 diabetes.Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).Have had within the past 90 days before screening: heart attack.Have had within the past 90 days before screening: stroke.Have had within the past 90 days before screening: hospitalization for unstable angina or heart failure.Have New York Heart Association Functional Classification Class IV congestive heart failure.Have a history of chronic or acute pancreatitis.Have taken weight loss drugs, including over-the-counter medications within 90 days prior to screening.
Sites
STAT Research - CABA
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Centro Médico Viamonte SRL - CABA, Buenos Aires
Cicemo
StudyTRIUMPH-9
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Obesity
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07357415
